EPO and Alzheimer disease: Thus, EPO and BDNF contents (ng/g tissue) in the AD+IHT group (EPO: 43.1 ± 8.7; BDNF: 22.4 ± 4.8) exceeded those in the pre-treatment 3xTg-AD mice (EPO: 18.1 ± 2.9; BDNF: 8.2 ± 1.6).